SCHEMBL16946

SCHEMBL16946

CC(C)(C)OC(=O)N[C@@H](CC1CCCCC1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 5/20 0.70
CTSS P25774 3/20 0.70
AAK1 Q2M2I8 2/20 0.49
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
GRN P28799 1/20 0.48
SORT1 Q99523 1/20 0.48
IDO1 P14902 1/20 0.46
CPB2 Q96IY4 2/20 0.45
CACNA1B Q00975 1/20 0.43
REN P00797 2/20 0.43
KMT2A Q03164 1/20 0.43
EPHX1 P07099 1/20 0.43
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSH P09668 1/20 0.42
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21427220 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
SCHEMBL9556128 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
SCHEMBL8283416 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
SCHEMBL9742291 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
SCHEMBL9742302 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
SCHEMBL482062 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
SCHEMBL16945 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
SCHEMBL21427213 1.00 CTSK (0.70) CTSKCTSSAAK1HDAC4HDAC1
Water SCHEMBL15646368 0.99 CTSK (0.73) CTSKCTSSAAK1HDAC4HDAC1
Water SCHEMBL266526 0.99 CTSK (0.73) CTSKCTSSAAK1HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112480122-B Tetrahydroimidazo [1,2-a ] pyrazine compound, composition, preparation method and application thereof 中山大学 2022-03-22 CN claimed
EP-0493087-B1 Process for the crystallisation of N-t-butyloxycarbonyl-3-cyclohexyl-L-alanine methyl ester AJINOMOTO KK (JP) 1996-03-13 EP claimed
US-5286897-A N-t-butyloxycarbonyl-3-cyclohexyl-L-alanine methyl ester in crystalline form AJINOMOTO CO., INC. (JP) 1994-02-15 US claimed
EP-0493087-A1 Process for the crystallisation of N-t-butyloxycarbonyl-3-cyclohexyl-L-alanine methyl ester Ajinomoto Co., Inc. (JP) 1992-07-01 EP claimed
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 US disclosed
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 US disclosed
EP-4702033-A1 DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF Imhotex Limited (GB) 2026-03-04 EP disclosed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 US disclosed
US-12371461-B2 Nemo coiled coil mimics and methods of using same NEW YORK UNIVERSITY (US) 2025-07-29 US disclosed
EP-3303367-B1 STABILIZED MINIMAL COILED-COIL MIMETICS UNIV NEW YORK (US) 2025-06-18 EP disclosed
CN-118845947-B Preparation process of dendrobium candidum composite particles for clearing liver and improving eyesight 江西省中医药研究院 2025-05-13 CN disclosed
CN-119930740-A Dipeptide compound, chimeric molecule based on dipeptide compound and application of dipeptide compound 西南交通大学 2025-05-06 CN disclosed
US-4885292-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1989-12-05 US disclosed
EP-0337295-A2 Renin-inhibiting N-heterocyclic dipeptides E.R. Squibb & Sons, Inc. (US) 1989-10-18 EP disclosed
WO-1989007940-A1 1,2-HYDROXY PHOSPHONATES AND DERIVATIVES THEREOF E.R. SQUIBB & SONS, INC. (US) 1989-09-08 WO disclosed
EP-0331105-A2 1,2-Hydroxy phosphonates and derivatives thereof E.R. Squibb & Sons, Inc. (US) 1989-09-06 EP disclosed
US-4603121-A ANALGESICS G. D. SEARLE & CO. (US) 1986-07-29 US disclosed
US-4514332-A Tetrapeptide adamantyl amides G. D. SEARLE & CO. (US) 1985-04-30 US disclosed
EP-0136720-A2 Enkephalin analogs G.D. Searle & Co. (US) 1985-04-10 EP disclosed
US-4495178-A Enkephalin analogs G. D. SEARLE & CO. (US) 1985-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371461-B2 Nemo coiled coil mimics and methods of using same COIL, CALCOCO2, NCAPH CTSK 4487/4885CTSS 4120/4885AAK1 2876/4885
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL CTSK 50/4885CTSS 7/4885AAK1 4588/4885
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS THRB, MC1R, MC5R CTSK 4651/4885CTSS 4268/4885AAK1 1634/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 CTSK 4676/4885CTSS 4503/4885AAK1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.